[ad_1]
Company announces SCINTIX as new product name for its flagship biology-guided radiotherapy technology
RefleXion® Medicala therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced eight clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, Oct. 23-26, in San Antonio. Additionally, ASTRO will serve as the setting for introducing SCINTIX™ as the new product name for RefleXion’s flagship BgRT technology and treatment, provided only through the company’s X1 platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221020005009/en/
RefleXion introduces SCINTIX™ as the new brand name for its flagship BgRT technology and treatment, provided only through the company’s X1 platform. (Photo: Business Wire)
“We are so pleased to once again have multiple posters and …
Full story available on Benzinga.com
[ad_2]
Source link
